Celltrion’s Omlyclo gains ground in major European markets, tops 90% share in Spain
Celltrion’s omalizumab biosimilar Omlyclo is showing rapid growth in major European markets.
Celltrion said on Sept. 10 that Omlyclo, used to treat chronic spontaneous urticaria and allergic asthma, is estimated to have surpassed a 90% market share in Spain as of July and has posted sales in Italy exceeding the company’s initial business targets. Omlyclo is..